Chemical formula: C₅H₁₁NO₄S Molecular mass: 181.21 g/mol PubChem compound: 71158
Acamprosate has a chemical structure similar to that of amino acid neuromediators, such as taurine or gamma-amino-butyric acid (GABA), including an acetylation to permit passage across the blood brain barrier. Acamprosate may act by stimulating GABAergic inhibitory neurotransmission and antagonising excitatory aminoacids, particularly glutamate. It is indicated as therapy to maintain abstinence in alcohol-dependent patients.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N07BB03 | Acamprosate | N Nervous system → N07 Other nervous system drugs → N07B Drugs used in addictive disorders → N07BB Drugs used in alcohol dependence |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| CAMPRAL Enterocoated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Acamprosate is an active ingredient of these brands:
Australia (AU)
Austria (AT)
Canada (CA)
Estonia (EE)
France (FR)
Ireland (IE)
Japan (JP)
Netherlands (NL)
Poland (PL)
South Africa (ZA)
Spain (ES)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
